Culturally adapted online genetic counseling and testing education for African American cancer survivors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Investigators will work with community stakeholders and clinical genetic professionals to adapt and refine an online genetic counseling education program tailored for at-risk African American cancer survivors. Participants enrolled in the Detroit ROCS cohort who receive care at Karmanos will provide consent and complete questionnaires before the online intervention, immediately after, and at 3 months. The primary aim is to measure whether the culturally adapted program increases uptake of genetic counseling and genetic testing. The team will also collaborate with community leaders to identify barriers and create a roadmap for wider dissemination of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS)
* Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1/1/2013
* have received or currently receiving care at Karmanos Cancer Institute
* meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below

Female breast

1. personal diagnosis at age ≤50
2. personal history of the triple-negative subtype
3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \<50
4. at least 1 close relative diagnosed with ovarian cancer
5. 2+ close relatives diagnosed with breast or prostate cancer
6. age \<50 AND another primary breast cancer at any age
7. 2+ primary breast cancers at any age

OR Prostate

1. personal history of high-risk or very high-risk prostate cancer
2. personal history of regional or metastatic prostate cancer
3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \<60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer)

OR Colorectal

1. personal diagnosis at age ≤50
2. at least 1 close relative diagnosed with HNPCC at age \<50
3. at least 2 close relatives diagnosed with an HNPCC cancer at any age
4. colorectal and \>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate

Exclusion Criteria:

* Previous genetic counseling and/or testing

Where it's running

• Karmanos Cancer Institute
  Detroit, Michigan, United States Recruiting

Study contacts

• Principal investigator: Felicity WK Harper, Ph.D — Barbara Ann Karmanos Cancer Institute
• Study coordinator: Jasminder Phalore, MPH
• Email: phalorej@karmanos.org
• Phone: 313-576-9735

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.